[AGTC] Applied Genetic Technologies Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 9.95 Change: 0.45 (4.74%)
Ext. hours: Change: 0 (0%)

chart AGTC

Refresh chart

Description: Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company?s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma. The company was founded in 1999 and is headquartered in Alachua, Florida.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS0.41 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 129.03% Sales Growth - Q/Q-56.44% P/E12.32
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-21.62% ROE-22.5% ROI
Current Ratio17.17 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin-1185.67% Net Profit Margin-1182.89% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities32.16 M Cash From Investing Activities16.78 M Cash From Operating Activities-13.08 M Gross Profit
Net Profit-6.33 M Operating Profit-6.39 M Total Assets96.58 M Total Current Assets65.11 M
Total Current Liabilities3.79 M Total Debt Total Liabilities3.79 M Total Revenue280 K
Technical Data
High 52 week10.05 Low 52 week3.4 Last close4.2 Last change-2.33%
RSI67.86 Average true range0.21 Beta1.51 Volume53.6 K
Simple moving average 20 days8.53% Simple moving average 50 days10.66% Simple moving average 200 days-9.89%
Performance Data
Performance Week-2.33% Performance Month16.67% Performance Quart7.69% Performance Half-14.29%
Performance Year-54.59% Performance Year-to-date16.67% Volatility daily2.87% Volatility weekly6.41%
Volatility monthly13.14% Volatility yearly45.51% Relative Volume237.74% Average Volume104.71 K
New High New Low

News

2019-03-06 05:00:00 | Applied Genetic Technologies- An Eye on Optogenetics

2019-02-26 09:25:02 | Will Applied Genetic Technologies Continue to Surge Higher?

2019-02-07 15:31:54 | Edited Transcript of AGTC earnings conference call or presentation 7-Feb-19 1:00pm GMT

2019-02-07 08:24:37 | Applied Genetic Technologies: Fiscal 2Q Earnings Snapshot

2019-02-07 07:00:00 | AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2018

2019-02-01 10:30:03 | Analysts Estimate Applied Genetic Technologies AGTC to Report a Decline in Earnings: What to Look Out for

2019-01-02 07:30:00 | New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications — Factors of Influence, Major Initiatives and Sustained Production

2018-12-21 12:04:56 | Applied Genetic Technologies Corporation NASDAQ:AGTC: Time For A Financial Health Check

2018-12-14 07:30:12 | Applied Genetic Technologies Enters Oversold Territory

2018-12-13 13:40:38 | Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?

2018-12-13 07:56:25 | The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

2018-12-13 06:55:00 | Today's Research Reports on Trending Tickers: Novavax and Applied Genetic Technologies

2018-12-12 16:01:00 | AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration

2018-11-15 08:45:00 | Consolidated Research: 2018 Summary Expectations for Tapestry, Mallinckrodt public limited company, Moxian, Applied Genetic Technologies, VistaGen Therapeutics, and Oasis Midstream Partners LP — Fundamental Analysis, Key Performance Indications

2018-11-09 18:38:01 | Edited Transcript of AGTC earnings conference call or presentation 8-Nov-18 1:00pm GMT

2018-11-08 08:55:01 | Applied Genetic Technologies AGTC Tops Q1 Earnings and Revenue Estimates

2018-11-08 07:51:36 | Applied Genetic Technologies: Fiscal 1Q Earnings Snapshot

2018-11-08 07:00:00 | AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2018

2018-11-01 07:00:00 | AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 8, 2018

2018-10-30 10:33:02 | Earnings Preview: Applied Genetic Technologies AGTC Q1 Earnings Expected to Decline

2018-09-27 07:00:00 | AGTC to Present at Upcoming Conferences

2018-09-24 17:15:35 | AGTC Appoints William Aliski to its Board of Directors

2018-09-24 09:29:26 | Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update

2018-09-11 23:48:02 | Applied Genetic Technologies Corp AGTC Files 10-K for the Fiscal Year Ended on June 30, 2018

2018-09-11 02:55:12 | Edited Transcript of AGTC earnings conference call or presentation 10-Sep-18 8:30pm GMT

2018-09-10 16:18:21 | Applied Genetic Technologies: Fiscal 4Q Earnings Snapshot

2018-09-10 16:03:00 | AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2018

2018-09-10 08:19:52 | Earnings Outlook for Applied Genetic Tech

2018-08-30 16:05:00 | AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 10, 2018

2018-08-08 16:05:00 | AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 15, 2018

2018-08-07 08:00:00 | Achroma Corp. Announces Global Survey Results of 226 People with Achromatopsia

2018-07-23 07:00:00 | AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10 Million Enrollment Milestone

2018-06-14 16:01:00 | AGTC Announces Expansion of Clinical and Regulatory Leadership Teams

2018-05-08 23:35:37 | Edited Transcript of AGTC earnings conference call or presentation 8-May-18 8:30pm GMT

2018-05-08 19:16:01 | Applied Genetic Technologies: Fiscal 3Q Earnings Snapshot

2018-05-08 16:05:00 | AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2018

2018-04-30 07:00:00 | AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 8, 2018

2018-04-18 07:00:00 | AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

2018-04-10 09:30:54 | AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis XLRS

2018-02-14 16:05:00 | AGTC Announces Sue Washer, CEO, Elected to Biotechnology Innovation Organization’s Board of Directors

2018-02-12 07:50:00 | Wired News – Catalyst Biosciences Shares Positive Top-line Data from Phase-1/2 Study of Subcutaneous CB 2679d for Hemophilia B

2018-02-11 17:13:31 | Edited Transcript of AGTC earnings conference call or presentation 9-Feb-18 1:00pm GMT

2018-02-09 07:35:17 | Applied Genetic Technologies posts 2Q loss

2018-02-09 07:00:00 | AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017

2018-02-09 06:30:00 | Applied Genetic Technologies Corp. to Host Earnings Call

2018-02-01 16:05:00 | AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 9, 2018

2017-12-25 11:39:44 | ETFs with exposure to Applied Genetic Technologies Corp. : December 25, 2017

2017-12-12 12:40:28 | ETFs with exposure to Applied Genetic Technologies Corp. : December 12, 2017

2017-12-11 16:20:01 | AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017

2017-12-01 10:22:50 | ETFs with exposure to Applied Genetic Technologies Corp. : December 1, 2017